Dr. Brig S Viswanath

Medical Degrees

• MBBS – Karnatak Medical College, Hubli, Karnatak University, Dharwad.
• MD (Gen. Med.) – Command Hospital, Airforce, Bangalore, Rajiv Gandhi University of Health Science, Bengaluru.
• DM (Med. Onco.) – Cancer Institute (WIA), Adyar, Chennai – The Tamilnadu MGR Medical University, Chennai.

Fellowships & Special Training

• Classified specialist in Medicine and Medical Oncology.

Major Cancer Types Treated

• Cholangiocarcinoma
• Hairy cell leukaemia
• Ovarian cysts
• Acute Lymphoblastic Leukaemia
• Renal Cell Carcinoma
• Hodgkin Lymphoma
• Langerhans Cell Histiocytosis
• Malignant Melanoma
• Gastric Cancer

Sub-specialties

• Medical Oncology
• Haemato-Oncology

Advanced Procedures Performed

• Chemotherapy Administration
• Immunotherapy
• Targeted Therapy
• Bone Marrow Transplants
• Biopsies for cancer diagnosis

Current & Past Hospital Affiliations

• Current Affiliations:
  • Dr Rela's Institute and Medical Centre, Chennai (Dec 2024 - Present)
• Past Affiliations:
  • Madras Cancer Care Foundation, Chennai (Apr 2021 - Feb 2025)
  • Command Hospital (WC) (May 2006 - May 2009)
  • Command Hospital (EC) (Jun 2009 – Jun 2011)
  • Army Hospital (R&R) (Jun 2012 - Jun 2018)
  • Command Hospital (CC), Lucknow (Jun 2018 - Jul 2020)
  • Military Hospital, Chennai (Jul 2020 – Apr 2021)
  • Army Medical Services (Apr 1991 - Apr 2021)

Academic & Research Roles

• Professor of Medicine and Medical Oncology
• Examiner for DNB Medical Oncology.
• Head of Department (HOD) and conducted MCI inspections.

Key Achievements & Contributions

• Over 20 years of extensive experience in treating cancer patients.
• Served as Senior Advisor and Consultant in Medical Oncology in the Indian Army.

Published Papers in Medical Journals

Co-authored papers:

• Two cases of refractory rheumatoid arthritis treated with Rituximab, Indian Journal of Rheumatology, Vol2, Issue 3,S27:sept 2007.
• Clinicopathological profile of bronchogenic carcinoma in a tertiary care hospital in eastern part of India, Clinical Cancer Investig J 2014;3:220-4.
• T- lymphoblastic lymphoma in an undiagnosed rheumatoid arthritis- A rare occurrence Indian Journal of Rheumatology,Vol. 10, Issue 1,p48-50, 2015.
• Changing paradigm in treatment of lung cancer, J Cancer Metasta Treat 2016;2:214-9.
• A case of metastatic insulinoma: Management and review of literature, OGH Reports, 2016; 5(2):79-81.
• Management of HER2-positive breast cancer: A review, J NTR Univ Health Sci 2016;5:87-92.
• Paraneoplastic limbic encephalitis forgotten etiology of altered sensorium, Int J Adv Med 2016;3:771-3.
• A Clinico demographic Study of Receptor status in Carcinoma Breast, J Carcinog 2016, 15:2(7 April 2016) (ACOS Abstracts):S162.
• Primary CNS Lymphoma in Immunocompetent Patient – Case Series, J Carcinog 2016, 15:2, 7 April 2016) (ACOS Abstracts):S215.
• Adenoid Cystic Carcinoma of Lung: A oncological rarity treated with definitive chemoradiation, Int JCancer Ther Oncol.2016; 4(3):4315.
• Incidence of K-RAS mutation in metastatic colorectal carcinoma and further to find any associated correlation between K-RAS mutation and various demographic and clinical factors. A Hospital based study(#652).
• To compare and determine the diagnostic accuracy of [18F]- fluorodeoxyglucose positron emission tomography scan in predicting pathological response in operated carcinoma esophagus patients after initial neoadjuvant chemoradiation and neoadjuvant chemotherapy, World J Nucl Med2018;17:79-85.

Notable Cases Handled

Dr. Brig S Viswanath has successfully managed countless patients with a wide array of cancers, employing various advanced treatment modalities to achieve positive outcomes. His extensive experience includes treating complex cases of Acute Lymphoblastic Leukaemia, Hodgkin Lymphoma, and various solid tumours, providing comprehensive care to patients from diverse backgrounds.

Patient Testimonials

• "Dr. Viswanath’s compassionate approach and clear explanations made my chemotherapy journey much less daunting. I felt genuinely cared for throughout my treatment." – Ramesh K.
• "Choosing Dr. Brig S Viswanath for my treatment was the best decision. His expertise in Medical Oncology is truly commendable, and his team provided exceptional support." – Priya S.
• "I am incredibly grateful to Dr. Viswanath for his unwavering dedication. His innovative treatment plan for my Renal Cell Carcinoma gave me a new lease on life." – Anjali M.

Patient-Centred Care

Dr. Brig S Viswanath adheres to a patient-centred care philosophy, prioritising the individual needs and well-being of each patient. He believes in clear communication, ensuring patients and their families are well-informed about their diagnosis, treatment options, and expected outcomes. His approach focuses on tailoring treatment plans to provide the most effective care while maintaining a high quality of life.

Technology & Innovation

Dr. Viswanath integrates the latest advancements in Medical Oncology into his practice, including state-of-the-art chemotherapy regimens, immunotherapy, and targeted therapy. He is dedicated to utilising evidence-based practices and innovative techniques to ensure optimal patient outcomes and continually improve cancer care.

For appointment booking and to get a personalised cost estimate, you can connect with the Cancer Rounds team.

Language Support

The Cancer Rounds team provides comprehensive language support to ensure international patients can communicate effectively with Dr. Brig S Viswanath and the medical staff. Dr. Viswanath is fluent in English, Hindi, Tamil, and Kannada.

Visa & Travel Assistance

The Cancer Rounds team offers dedicated assistance with visa applications, travel arrangements, airport transfers, and comfortable accommodation options for international patients and their accompanying family members.

Pre-treatment Virtual Consultations

International patients can benefit from pre-treatment virtual consultations with Dr. Brig S Viswanath. This allows for an initial assessment, review of medical records, and discussion of potential treatment plans before travelling to India.